UY32228A - Nueva clase de compuestos de pirrolidina, composiciones conteniéndolas y aplicaciones - Google Patents

Nueva clase de compuestos de pirrolidina, composiciones conteniéndolas y aplicaciones

Info

Publication number
UY32228A
UY32228A UY0001032228A UY32228A UY32228A UY 32228 A UY32228 A UY 32228A UY 0001032228 A UY0001032228 A UY 0001032228A UY 32228 A UY32228 A UY 32228A UY 32228 A UY32228 A UY 32228A
Authority
UY
Uruguay
Prior art keywords
compounds
compositions containing
pirrolidine
applications
new class
Prior art date
Application number
UY0001032228A
Other languages
English (en)
Spanish (es)
Inventor
Kevin Neil Dack
James Edward John Mills
Sarah Elizabeth Skerratt
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of UY32228A publication Critical patent/UY32228A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY0001032228A 2008-11-10 2009-11-09 Nueva clase de compuestos de pirrolidina, composiciones conteniéndolas y aplicaciones UY32228A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11286908P 2008-11-10 2008-11-10

Publications (1)

Publication Number Publication Date
UY32228A true UY32228A (es) 2010-06-30

Family

ID=41503565

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032228A UY32228A (es) 2008-11-10 2009-11-09 Nueva clase de compuestos de pirrolidina, composiciones conteniéndolas y aplicaciones

Country Status (31)

Country Link
US (1) US8278343B2 (enExample)
EP (1) EP2364296A1 (enExample)
JP (1) JP2012508225A (enExample)
KR (1) KR20110083733A (enExample)
CN (1) CN102209710A (enExample)
AP (1) AP2011005728A0 (enExample)
AR (1) AR074314A1 (enExample)
AU (1) AU2009312427B2 (enExample)
BR (1) BRPI0920924A2 (enExample)
CA (1) CA2741589A1 (enExample)
CL (1) CL2011001034A1 (enExample)
CO (1) CO6382112A2 (enExample)
CR (1) CR20110217A (enExample)
CU (1) CU20110093A7 (enExample)
DO (1) DOP2011000127A (enExample)
EA (1) EA201100549A1 (enExample)
EC (1) ECSP11011032A (enExample)
GE (1) GEP20125607B (enExample)
IL (1) IL212490A0 (enExample)
MA (1) MA32782B1 (enExample)
MX (1) MX2011004903A (enExample)
NI (1) NI201100092A (enExample)
NZ (1) NZ592311A (enExample)
PA (1) PA8848001A1 (enExample)
PE (1) PE20110663A1 (enExample)
SV (1) SV2011003896A (enExample)
TN (1) TN2011000211A1 (enExample)
TW (1) TW201022234A (enExample)
UY (1) UY32228A (enExample)
WO (1) WO2010052625A1 (enExample)
ZA (1) ZA201104310B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074776A1 (es) * 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ep2受體拮抗劑之新穎2h-吲唑
WO2013176220A1 (ja) * 2012-05-25 2013-11-28 国立大学法人京都大学 概日リズム調整
CN110041269A (zh) * 2019-05-16 2019-07-23 海门瑞一医药科技有限公司 一种2-氯-5-羟基嘧啶的制备方法
EP4359399A4 (en) * 2021-06-24 2025-04-23 Reservoir Neuroscience, Inc. EP2 antagonist compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69221794T2 (de) * 1991-01-21 1998-03-19 Shionogi Seiyaku Kk 3-benzyliden-1-carbamoyl-2-pyrrolidon-analoga
DE60235198D1 (de) * 2001-12-20 2010-03-11 Merck Serono Sa Coinsins Pyrrolidin-derivatie als prostaglandin-modulatoren
WO2007005176A1 (en) * 2005-06-29 2007-01-11 Allergan, Inc. Pyrrolidinones for the treatment of glaucoma and ocular hypertension
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7550448B2 (en) * 2006-05-24 2009-06-23 Allergan, Inc. Therapeutic compounds
DE102006039912A1 (de) * 2006-08-25 2008-03-20 Bayer Healthcare Ag Substituierte Spirotetronsäuren und ihre Verwendung
BRPI0811444A2 (pt) * 2007-05-10 2014-10-29 Pfizer Ltd Derivados de azetidina e seu uso como antagonistas da prostaglandina e2.

Also Published As

Publication number Publication date
TN2011000211A1 (fr) 2012-12-17
US8278343B2 (en) 2012-10-02
AU2009312427A1 (en) 2010-05-14
NI201100092A (es) 2011-10-31
KR20110083733A (ko) 2011-07-20
JP2012508225A (ja) 2012-04-05
EP2364296A1 (en) 2011-09-14
ZA201104310B (en) 2012-02-29
CU20110093A7 (es) 2012-01-31
TW201022234A (en) 2010-06-16
MX2011004903A (es) 2011-05-30
MA32782B1 (fr) 2011-11-01
PA8848001A1 (es) 2010-06-28
EA201100549A1 (ru) 2011-12-30
CO6382112A2 (es) 2012-02-15
AR074314A1 (es) 2011-01-05
CA2741589A1 (en) 2010-05-14
CN102209710A (zh) 2011-10-05
GEP20125607B (en) 2012-08-10
DOP2011000127A (es) 2011-07-15
AU2009312427B2 (en) 2011-10-20
IL212490A0 (en) 2011-06-30
BRPI0920924A2 (pt) 2016-10-04
CR20110217A (es) 2011-05-12
ECSP11011032A (es) 2011-06-30
CL2011001034A1 (es) 2011-11-11
SV2011003896A (es) 2011-07-05
WO2010052625A1 (en) 2010-05-14
AP2011005728A0 (en) 2011-06-30
NZ592311A (en) 2012-12-21
US20100120793A1 (en) 2010-05-13
PE20110663A1 (es) 2011-09-23

Similar Documents

Publication Publication Date Title
MX2021010674A (es) Compuestos triciclicos condensados utiles como agentes anticancerigenos.
CO6321265A2 (es) Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso
PA8827901A1 (es) Derivados de quinoxalin- y quinolin-carboxamida
PE20211427A1 (es) Compuestos terapeuticos utiles para el tratamiento profilatico o terapeutico de una infeccion por el virus del vih
GT201400079A (es) Derivados de (4-fenilimidazol-2-il) etilamina útiles como moduladores de canal de sodio
NI201100137A (es) Derivados de sulfonamida
UY31063A1 (es) Derivados de n-[6-amino-5-aril-piridin -2-il]-carboxamida, composiciones conteniéndolos, procedimientos de preparación, itermedios utilizados en la preparación y aplicaciones.
CY1116328T1 (el) Παραγωγα 4 - αμινοπυριμιδινης και η χρηση τους ως ανταγωνιστων α2α υποδοχεων αδενοσινης
ECSP11011032A (es) Pirrolidinas
MX2013003036A (es) Derivados de pirazina como bloqueadores de enac.
CU20170144A7 (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores gamma ror
CL2012000925A1 (es) Compuestos derivados de tetrahidrociclohepta[b]piridinilo, antagonista del receptor de cgrp; composicion farmaceutica que lo comprende; y su uso en el tratamiento de migraña, cefalea, diabetes, cancer, entre otras.
MX2020014156A (es) Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4.
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
CL2009000368A1 (es) 3-(amido o sulfamido)-4-(4-azinil sustituido) benzamidas o benzosulfonamidas; la composicion farmaceutica que los contiene; el uso de los compuestos; y un kit que contiene dichos compeustos; utiles como inhibidores del receptor de quimioquinas cxcr3.
CO6420342A2 (es) Derivados de pirazol usados como antagonistas del receptor ccr4
CR11101A (es) Azetidinas
ECSP10010606A (es) Derivados de quinuclidina como antagonistas de receptores muscarinicos m3
UY35708A (es) Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico
CR20220299A (es) Derivados de becimidazol
AR071721A1 (es) Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno.
HN2012001923A (es) Hidrato del hidrocloruro de agomelatina y preparacopn de este
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
MX2022011354A (es) Compuestos de pirimidina fusionados como moduladores de kcc2.
CO6690116A1 (es) Nueva asociación entre la 4-[3-(cis-hexahidrociclopenta[c]pirrol -2(1h)-il]propoxi]benzamida y un antagonista de los receptores nmda y las composiciones famacéuticas que las contienen

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181127